Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. filed an S-1MEF registration statement to increase the number of common shares offered and registered in its public offering. The company is registering an additional 3,680,000 shares, which includes 480,000 shares subject to the underwriters' option to purchase additional stock. This filing is made pursuant to Rule 462(b) and incorporates the earlier S-1 registration statement (File No. 333-297518), which became effective on August 6, 2026.

Latigo Biotherapeutics, a clinical-stage biopharmaceutical company, filed an S-1/A registration statement for an initial public offering of 16,000,000 shares of common stock, expected to price between $16.00 and $18.00 per share and list on Nasdaq under "LTGO". The company highlighted positive data for its lead non-opioid pain candidate, LTG-001, in a pivotal abdominoplasty trial, which met its primary endpoint with high statistical significance and showed superior analgesic effect and rapid onset compared to Vicodin. Proceeds from the IPO will fund the advancement of LTG-001 into Phase 3 trials and further development of its pipeline, despite reporting substantial net losses in recent years.

Latigo Biotherapeutics, Inc. filed an S-1/A for its initial public offering, proposing to sell 16,000,000 shares of common stock at an expected price range of $16.00 to $18.00 per share. The company, focused on non-opioid pain medicines, reported positive Phase 3 results for its lead candidate LTG-001 in an abdominoplasty trial, meeting its primary endpoint and demonstrating significant opioid sparing. It also plans to initiate further Phase 3 trials for LTG-001 and a Phase 2 trial for LTG-321.